- Home
- JGH vs ZNTL Comparison
JGH vs ZNTL Comparison
Compare JGH & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- ZNTL
- Stock Information
- Founded
- JGH 2014
- ZNTL 2014
- Country
- JGH United States
- ZNTL United States
- Employees
- JGH N/A
- ZNTL N/A
- Industry
- JGH Investment Managers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- ZNTL Health Care
- Exchange
- JGH Nasdaq
- ZNTL Nasdaq
- Market Cap
- JGH 304.1M
- ZNTL 238.2M
- IPO Year
- JGH N/A
- ZNTL 2020
- Fundamental
- Price
- JGH $12.97
- ZNTL $3.12
- Analyst Decision
- JGH
- ZNTL Buy
- Analyst Count
- JGH 0
- ZNTL 7
- Target Price
- JGH N/A
- ZNTL $10.86
- AVG Volume (30 Days)
- JGH 73.9K
- ZNTL 1.2M
- Earning Date
- JGH 01-01-0001
- ZNTL 11-04-2024
- Dividend Yield
- JGH 9.85%
- ZNTL N/A
- EPS Growth
- JGH N/A
- ZNTL N/A
- EPS
- JGH N/A
- ZNTL N/A
- Revenue
- JGH N/A
- ZNTL $40,560,000.00
- Revenue This Year
- JGH N/A
- ZNTL N/A
- Revenue Next Year
- JGH N/A
- ZNTL N/A
- P/E Ratio
- JGH N/A
- ZNTL N/A
- Revenue Growth
- JGH N/A
- ZNTL N/A
- 52 Week Low
- JGH $10.36
- ZNTL $2.83
- 52 Week High
- JGH $12.85
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- JGH 38.66
- ZNTL 44.34
- Support Level
- JGH $12.99
- ZNTL $2.92
- Resistance Level
- JGH $13.15
- ZNTL $3.23
- Average True Range (ATR)
- JGH 0.11
- ZNTL 0.17
- MACD
- JGH -0.05
- ZNTL 0.00
- Stochastic Oscillator
- JGH 13.73
- ZNTL 38.33
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.